Every 340B covered entity eventually asks the same question: What should our capture rate be?

The honest answer is that there is no single industry number. Capture rate depends on your pharmacy channel, payer mix, therapeutic mix, number of sites, prescriber behavior, referral patterns, manufacturer restrictions, and the denominator used in the calculation.

HRSA and the Office of Pharmacy Affairs do not publish a universal 340B capture rate benchmark. Capture rate is a management metric, not a compliance standard. HRSA focuses on requirements such as patient eligibility, diversion prevention, duplicate discount prevention, registered locations, and auditable records.[1][2]

That does not make benchmarking unimportant. It makes definition and segmentation essential.

A five-point gap can compound quietly. For example, if your entity has 20,000 eligible prescriptions per year and an illustrative net yield of $100 per captured prescription, a five-point gap represents approximately $100,000 in uncaptured annual value. The calculation is illustrative, not a published industry estimate. The financial principle is real.

What Capture Rate Actually Measures

A practical definition is:

Capture rate = qualified 340B dispenses captured through an approved channel divided by all eligible dispenses available to be captured.

Depending on your program design, the numerator may include prescriptions that were:

Routed to an entity-owned pharmacy.
Filled at a registered contract pharmacy.
Qualified by a third-party administrator.
Replenished against 340B inventory.
Submitted through an applicable manufacturer data platform.

The denominator should represent all eligible prescriptions or dispensing opportunities in the defined population, not simply the claims your vendor successfully received.

That distinction creates the largest benchmarking problem. One vendor may calculate capture as:

Claims filled through a 340B pharmacy ÷ all prescriptions written by covered-entity providers

Another may calculate:

Qualified 340B claims ÷ claims received by the TPA

A third may exclude restricted NDCs, reversals, Medicaid carve-outs, or external referrals before calculating the denominator.

Those figures cannot be compared without a definition audit.

Your Definition Audit Checklist

Before accepting any capture rate, confirm:

What exactly is the denominator?
Are prescriptions, patients, fills, or claims being counted?
Are refills included?
Are reversed claims removed?
Are manufacturer-restricted NDCs included or excluded?
Are Medicaid carve-outs included?
Are external referrals included?
Are in-house and contract pharmacy claims combined?
Is the metric based on written prescriptions, dispensed prescriptions, or qualified claims?
Can every numerator and denominator record be traced back to a source system?

Document the definition, data sources, exclusions, reporting period, and owner. Use the same methodology month over month.

Capture Rate Is Not Net Yield

Capture rate tells you whether an opportunity entered your 340B channel. It does not tell you whether the transaction produced useful financial value.

A high capture rate can coexist with weak performance if your entity has:

High dispensing fees.
Low reimbursement.
Frequent reversals.
Manufacturer restrictions.
Poor inventory replenishment.
Uncollected receivables.
High administrative costs.
Claims that qualify operationally but produce little net savings.

Your CFO-grade metric is net yield:

Net yield = realized reimbursement minus net acquisition cost, fees, operational cost, and leakage.

You should also monitor billed-to-collected performance. A claim that is captured and billed but never collected is not equivalent to realized savings.

For a broader financial framework, review Is 340B Still Worth It in 2027? A CFO’s Value Framework and 340B Chargebacks 101.

340B compliance dashboard showing claims, savings, and operational performance metrics

Bucket 1: In-House Pharmacy Capture

Entity-owned pharmacies usually have the greatest ability to influence capture because the pharmacy, prescribers, patient-routing process, and service model can be managed within the same organization.

What drives in-house capture?

Prescriber ordering and referral behavior.
EHR and point-of-dispensing workflows.
Formulary alignment.
Pharmacy location and operating hours.
Insurance acceptance.
Patient education.
Refill reminders.
Delivery, curbside, or mail options.
Inventory availability.
Wait times and service quality.
Coordination between clinic and pharmacy staff.

The most common in-house leaks are operational:

A provider sends the prescription to an outside retail pharmacy by default.
The in-house pharmacy does not accept a payer or manufacturer product.
The patient cannot wait for the prescription.
The pharmacy lacks evening or weekend access.
A medication is out of stock.
Refill outreach is inconsistent.
Referral prescriptions are not connected to the covered entity’s records.

Illustrative in-house planning ranges

The following are illustrative internal planning ranges, not published industry statistics and not HRSA benchmarks:

In-house capture rate	Directional interpretation
Below 60%	Significant leakage or access barriers likely require investigation
60% to 80%	Developing to functional performance, depending on patient and payer mix
Above 80%	Strong performance may be possible when routing, access, and inventory are well controlled

These ranges should never be applied without context. A rural entity with limited hours and a high external referral volume may have a different addressable opportunity than a multi-site FQHC with an integrated pharmacy.

Start with the five in-house pharmacy optimization actions, then compare performance by provider and site.

Bucket 2: Contract Pharmacy Capture

Contract pharmacy performance must be evaluated differently. A contract pharmacy expands patient access, but it also introduces additional data, timing, and qualification dependencies.

Key drivers include:

Referral documentation quality.
Prescriber and site affiliation data.
TPA matching logic.
Data-feed latency.
Pharmacy staff awareness of the relationship.
NDC and manufacturer restrictions.
Claims that dispense but fail qualification.
Reversals and rebills.
Medicaid status and duplicate discount controls.
Patient choice and geographic access.

A raw contract pharmacy capture rate is often incomparable across drugs. Manufacturer restrictions or NDC exclusions may mechanically suppress capture for one product while leaving another product unaffected.

Your contract pharmacy dashboard should therefore segment results by:

Contract pharmacy.
NDC.
Manufacturer.
Therapeutic class.
Payer.
Prescriber.
Site.
Qualification failure reason.

Use the GapRx contract pharmacy solution to evaluate network performance, oversight, and claims-level leakage. For claims workflow controls, see 8 Best Practices for 340B Claims Management.

The Metrics That Actually Predict Savings

Capture rate is a lagging summary measure. The following leading indicators tell you what to fix before the quarter closes.

Leading indicator	Why it matters
Eligible prescriptions by prescriber	Identifies providers with large addressable opportunity
Referral capture at prescribing	Shows whether the patient is routed before leakage occurs
Qualification failure rate	Reveals data, eligibility, payer, or matching problems
Top qualification failure reasons	Converts a percentage into an action plan
Uncaptured eligible dispense value	Prioritizes leakage by financial impact
Time to submission	Identifies delays that threaten pricing or reimbursement
Exception aging	Shows whether unresolved claims are becoming unrecoverable
Reversal rate	Indicates workflow, inventory, payer, or patient-access friction
Fill-to-qualification cycle time	Measures operational speed and data-feed health

Lagging indicators remain important:

Net savings.
Net yield per claim.
Savings per site.
Cost per captured prescription.
Billed-to-collected percentage.
Rebate or credit recovery.
Total program value.

Leading indicators are the measures you can act on inside a quarter. Lagging indicators tell you whether the response worked.

Segment Before You Benchmark

A blended entity-wide number often hides the problem. Segment capture by:

Channel: in-house, contract pharmacy, or both.
Site: each clinic, service area, and pharmacy location.
Prescriber: provider, department, and specialty.
Payer: Medicaid, Medicare, commercial, and cash.
Therapeutic class: primary care, specialty, chronic care, and acute care.
NDC and manufacturer: especially where restrictions apply.

Illustrative example

Suppose Site A has 900 eligible prescriptions and captures 90%. Site B has 100 eligible prescriptions and captures 20%.

The blended result is:

Captured prescriptions: 810 plus 20, or 830
Total eligible prescriptions: 1,000
Blended capture rate: 83%

The 83% figure looks strong, but Site B is losing 80% of its eligible opportunity. A site-level view directs leadership toward the actual problem.

The same principle applies to contract pharmacy claims. A strong result for unrestricted generic drugs can conceal poor performance for restricted specialty NDCs.

A Practical Self-Scoring Instrument

Score each indicator using your own documented data. These are internal management thresholds, not external industry benchmarks.

Indicator	Lagging, 0 points	Developing, 1 point	Strong, 2 points
Definition documented	No	Partially	Complete and approved
Source-to-report reconciliation	Not performed	Periodic	Monthly and documented
Site segmentation	None	Some sites	All sites
Prescriber segmentation	None	Limited	Complete
Qualification failure rate	Unknown or worsening	Measured	Trended with root causes
Uncaptured value	Unknown	Estimated	Ranked by impact
Submission timeliness	Unknown	Monitored	Target consistently met
Exception aging	Over 60 days	31 to 60 days	Under 30 days
Reversal rate	Unknown or worsening	Measured	Trended and acted upon
NDC/manufacturer segmentation	None	Partial	Complete for contract claims
Net yield reporting	Not available	Quarterly	Monthly by channel
Leadership review	Irregular	Quarterly	Monthly with assigned actions

Score interpretation

0 to 8 points: Reporting risk. Establish a defensible baseline before setting targets.
9 to 16 points: Developing program. Address the weakest data and workflow dimensions first.
17 to 24 points: Strong management discipline. Focus on optimization, net yield, and strategic channel decisions.

Your lowest-scoring dimension should become the first 90-day priority.

A 90-Day Benchmarking Cadence

Weekly

Owned by the 340B coordinator, pharmacy operations, or analytics team:

Review new qualification failures.
Review uncaptured eligible value.
Track reversals and aging exceptions.
Escalate data-feed or inventory issues.
Monitor high-value NDCs.

Monthly

Owned jointly by finance, pharmacy, compliance, and program leadership:

Reconcile source records to vendor reports.
Review capture by channel, site, prescriber, payer, and therapeutic class.
Calculate net yield and billed-to-collected results.
Review manufacturer restrictions and submission status.
Assign corrective actions with due dates.

Quarterly

Owned by executive leadership or the 340B steering committee:

Reassess the denominator and methodology.
Review trends and root causes.
Evaluate contract pharmacy network performance.
Review in-house pharmacy access and operating model.
Compare program value with total cost of compliance.
Approve investment or remediation priorities.

A consolidated 340B analytics and dashboard solution can make this cadence repeatable instead of spreadsheet-dependent.

Red Flags That Your Capture Rate Is Wrong

Investigate immediately if:

The denominator excludes difficult drugs without a documented reason.
External referrals disappear from the opportunity base.
Reversals are not counted or tracked.
The vendor cannot provide source-level records.
The reported number changes when the reporting period changes.
In-house and contract pharmacy figures use different definitions.
Manufacturer-restricted NDCs are silently excluded.
A capture rate rises while net savings and collections fall.
No one can explain qualification failures.
The report contains percentages without counts, value, or data lineage.

A high number that cannot be reproduced is not a benchmark. It is an unverified assumption.

Frequently Asked Questions

What is a good 340B capture rate?

There is no universal good rate, and HRSA does not publish one. As an illustrative planning framework, many entities may use below 60% as a signal for investigation, 60% to 80% as a developing range, and above 80% as a strong internal result when the denominator is complete and the patient, payer, and channel mix are comparable. The right target is the highest defensible capture of addressable eligible volume without compromising patient choice or compliance.

Is in-house capture usually higher than contract pharmacy capture?

It can be, because your entity controls more of the workflow. However, in-house performance may suffer from limited hours, inventory problems, or payer restrictions. Contract pharmacy performance may be stronger for patient access but weaker for data matching, manufacturer restrictions, or referral documentation.

Should manufacturer-restricted drugs be included?

They should be included in a transparent opportunity analysis, but reported separately when restrictions mechanically limit capture. Do not mix restricted and unrestricted NDCs into one number and call the result comparable.

How often should capture rate be measured?

Review leading indicators weekly, reconcile performance monthly, and conduct a formal benchmark review quarterly. The methodology should remain stable unless a documented program change requires revision.

What should CFOs ask for first?

Ask for the formula, denominator, source systems, channel segmentation, uncaptured value, net yield, exception aging, and reconciliation evidence. If those items are unavailable, the first priority is measurement integrity.

Build a Defensible Baseline With GapRx

“Good” 340B capture is not a single percentage. It is a defensible measurement system that shows where eligible opportunities originate, where they leak, which claims qualify, what value is realized, and what action will improve performance.

GapRx 340B Consultants LLC helps covered entities build that visibility through advanced analytics, program dashboards, in-house pharmacy optimization, contract pharmacy oversight, claims management, and compliance support.

Schedule a 30-minute 340B strategy call with GapRx to review your current capture-rate definition, identify the highest-value leakage points, and establish a reliable baseline for 2026.

Sources

This article is for educational and operational planning purposes. It is not legal, regulatory, or compliance advice. Review current HRSA, OPA, payer, state Medicaid, manufacturer, and contractual requirements with your qualified advisors.

Capture Rate Benchmarks: What “Good” Actually Looks Like in 2026